EPIDUO 0.1%/2.5%  adapalene / benzoyl peroxide gel bottle Australia - English - Department of Health (Therapeutic Goods Administration)

epiduo 0.1%/2.5% adapalene / benzoyl peroxide gel bottle

galderma australia pty ltd - adapalene, quantity: 1 mg/g; benzoyl peroxide, quantity: 25 mg/g - gel - excipient ingredients: poloxamer; docusate sodium; purified water; glycerol; disodium edetate; propylene glycol; polysorbate 80; acrylamide/sodium acryloyldimethyltaurate copolymer; isohexadecane; sorbitan oleate - cutaneous treatment of acne vulgaris on the face, chest and back when comedones, papules and pustules are present, and the condition has not responded to first line treatment.

BENZOYL PEROXIDE gel United States - English - NLM (National Library of Medicine)

benzoyl peroxide gel

cintex services, llc - benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - benzoyl peroxide 100 mg in 1 g - for the treatment of acne - have very sensitive skin - are sensitive to benzoyl peroxide stop use and ask a doctor if   irritation becomes severe.

BENZOYL PEROXIDE- benzoyl peroxide aerosol, foam United States - English - NLM (National Library of Medicine)

benzoyl peroxide- benzoyl peroxide aerosol, foam

cintex services, llc - benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - benzoyl peroxide 98 mg in 1 g - acne treatment for the treatment of acne do not use if you - have very sensitive skin - are sensitive to benzoyl peroxide stop use and ask a doctor if irritation becomes severe.

zegerid with magnesium hydroxide- omeprazole, sodium bicarbonate and magnesium hydroxide tablet, chewable United States - English - NLM (National Library of Medicine)

zegerid with magnesium hydroxide- omeprazole, sodium bicarbonate and magnesium hydroxide tablet, chewable

santarus, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (sodium bicarbonate - unii:8mdf5v39qo), magnesium hydroxide (unii: nbz3qy004s) (magnesium hydroxide - unii:nbz3qy004s) - tablet, chewable - 20 mg - zegerid with magnesium hydroxide is indicated for short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. zegerid with magnesium hydroxide is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. (see clinical pharmacology, clinical studies, gastric ulcer.) zegerid with magnesium hydroxide is indicated for the treatment of heartburn and other symptoms associated with gerd. zegerid with magnesium hydroxide is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. (see clinical pharmacology, clinical studies.) the efficacy of zegerid with magnesium hydroxide used for longer than 8 weeks in these patients has not been established. in the rare instance of a patient not responding to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. if there is recurrence of erosive esophagitis or gerd symptoms (eg, hea

INOMAX- nitric oxide gas United States - English - NLM (National Library of Medicine)

inomax- nitric oxide gas

ino therapeutics llc - nitric oxide (unii: 31c4ky9esh) (nitric oxide - unii:31c4ky9esh) - nitric oxide 0.98 mg in 1 l - inomax® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. inomax is contraindicated in neonates dependent on right-to-left shunting of blood. the safety and efficacy of nitric oxide for inhalation has been demonstrated in term and near-term neonates with hypoxic respiratory failure associated with evidence of pulmonary hypertension [see clinical studies (14.1)]. additional studies conducted in premature neonates for the prevention of bronchopulmonary dysplasia have not demonstrated substantial evidence of efficacy [see clinical studies (14.3)]. no information about its effectiveness in other age populations is available. nitric oxide is not indicated for use in the adult population.

BENZOYL PEROXIDE 5% GEL- benzoyl peroxide gel United States - English - NLM (National Library of Medicine)

benzoyl peroxide 5% gel- benzoyl peroxide gel

axia medical solutions, llc - benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - benzoyl peroxide 50 mg in 1000 mg - acne treatment for the treatment of acne. • have sensitive skin. • are sensitive to benzoyl peroxide. irritation become severe.

BENZOYL PEROXIDE 10% GEL- benzoyl peroxide gel United States - English - NLM (National Library of Medicine)

benzoyl peroxide 10% gel- benzoyl peroxide gel

axia medical solutions, llc - benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - benzoyl peroxide 100 mg in 1 g - acne treatment for the treatment of acne. • have sensitive skin. • are sensitive to benzoyl peroxide. irritation become severe.

EPIDUO adapalene / benzoyl peroxide 0.1%/2.5% gel tube Australia - English - Department of Health (Therapeutic Goods Administration)

epiduo adapalene / benzoyl peroxide 0.1%/2.5% gel tube

galderma australia pty ltd - adapalene, quantity: 1 mg/g; benzoyl peroxide, quantity: 25 mg/g - gel - excipient ingredients: poloxamer; docusate sodium; purified water; glycerol; disodium edetate; propylene glycol; polysorbate 80; acrylamide/sodium acryloyldimethyltaurate copolymer; isohexadecane; sorbitan oleate - cutaneous treatment of acne vulgaris on the face, chest and back when comedones, papules and pustules are present, and the condition has not responded to first line treatment.

INOmax nitric oxide 800 ppm medicinal gas for inhalation cylinder Australia - English - Department of Health (Therapeutic Goods Administration)

inomax nitric oxide 800 ppm medicinal gas for inhalation cylinder

ikaria australia pty ltd - nitric oxide, quantity: 0.08 % w/w - gas, medicinal - excipient ingredients: nitrogen - inomax?, in conjunction with ventilatory support and other appropriate agents, is indicated -,- for the treatment of term and near-term ( greater than 34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.,- to selectively decrease pulmonary arterial pressure in patients with perioperative pulmonary hypertension in conjunction with heart surgery